Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) presented data at the 2026 American Society of Clinical Psychopharmacology Annual Meeting revealing that opioid use remains prevalent among U.S. adults diagnosed with fibromyalgia, despite longstanding treatment guidelines discouraging their use. The findings, based on a retrospective analysis of more than 261,000 patients in the Symphony Health claims database, show that approximately 40% of commercially insured, Medicare Advantage, and Medicaid patients with fibromyalgia were prescribed at least one opioid. Tramadol and oxycodone were the most common prescriptions.
Tonix stated that the results underscore a significant gap between clinical practice and evidence-based recommendations. The company emphasized the need for greater awareness of FDA-approved, non-opioid treatment options, including its recently approved fibromyalgia therapy TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg). TONMYA is the first new treatment for fibromyalgia in more than 15 years and offers an alternative to opioids for managing this chronic pain condition.
The implications of this study are far-reaching for patients, healthcare providers, and the pharmaceutical industry. For patients, the data highlight the ongoing reliance on opioids, which carry risks of addiction, overdose, and other adverse effects. For healthcare providers, the findings may prompt a reassessment of prescribing practices and increased consideration of non-opioid therapies. For the industry, Tonix’s presentation positions TONMYA as a potentially safer alternative, addressing an unmet medical need in a large patient population.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. In addition to TONMYA, the company’s CNS commercial infrastructure supports its acute migraine products, Zembrace SymTouch and Tosymra. Tonix is also evaluating TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder. The company’s pipeline includes TNX-2900 for Prader-Willi syndrome and immunology programs such as TNX-4800 for Lyme disease prophylaxis and TNX-1500 for kidney transplant rejection.
The full press release detailing the study results can be found at https://ibn.fm/6AtjR. For more information about Tonix and its product candidates, visit the company’s newsroom at https://ibn.fm/TNXP.
This data presentation serves as a critical reminder of the challenges in managing fibromyalgia and the importance of adhering to evidence-based guidelines. As the opioid crisis continues to affect communities, the availability of effective non-opioid treatments like TONMYA could play a pivotal role in reducing opioid prescriptions and improving patient outcomes.
